Quoin Pharmaceuticals, Ltd.
QNRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $4 | $3 | $3 | $2 |
| G&A Expenses | $6 | $6 | $7 | $4 |
| SG&A Expenses | $6 | $6 | $7 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $10 | $9 | $9 | $6 |
| Operating Income | -$10 | -$9 | -$9 | -$6 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1 | $1 | -$0 | -$15 |
| Pre-Tax Income | -$9 | -$9 | -$9 | -$21 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$9 | -$9 | -$9 | -$21 |
| % Margin | – | – | – | – |
| EPS | -66.85 | -337.47 | -22.97 | -28,543.2 |
| % Growth | 80.2% | -1,369.2% | 99.9% | – |
| EPS Diluted | -66.85 | -337.47 | -22.97 | -28,543.2 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $0 | $0 |
| Interest Expense | $0 | $0 | $1 | $1 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$9 | -$9 | -$9 | -$20 |
| % Margin | – | – | – | – |